The prognostic significance of surgical staging for carcinoma of the endometrium.

Abstract:

:This study is based on a retrospective review of 156 patients with endometrial carcinoma from 1978 through 1984 who underwent primary surgical evaluation. All cases were retrospectively restaged using the newly adopted FIGO surgical staging. The preoperative FIGO clinical stage distribution for this study was as follows: 121 (77.6%) Stage I, 22 (14.1%) Stage II, 5 (3.2%) Stage III, 2 (1.3%) Stage IV, and 6 (3.8%) unstaged patients. Most patients had TAH-BSO with a collection of peritoneal washings and retroperitoneal lymph node sampling. Surgical staging revealed 122 (78.2%) Stage I, 9 (5.8%) Stage II, 12 (7.7%) Stage III, and 13 (8.3%) Stage IV patients. Surgery upstaged 12.4% of clinical Stage I. In clinical stage II, 59.0% were downstaged while 27.3% were upstaged. For clinical Stage III, 60.6% were upstaged, but no downstaging occurred. No change in stage occurred for clinical Stage IV patients. Ninety-seven surgically staged patients received no adjuvant therapy. The remaining 59 patients had adjunctive treatment which consisted of radiotherapy (59.3%), hormonal therapy (25.4%), chemotherapy (5.1%), or combined modality treatment (10.2%). All patients were followed until death or a minimum of 5 years (60-139 months; median, 82 months) with the exception of 13 patients who were lost to follow-up (2-58 months; median, 34 months). Five-year survival by clinical staging was as follows: 86.2% for Stage I, 85.9% for Stage II, and 0% for Stage III and IV. Five-year survival by surgical staging was 90.6% for Stage I, 85.7% for Stage II, 58.3% for Stage III, and 0% for Stage IV. The 13 patients who were lost to follow-up were censored in all survival analyses at the time of last contact. Stepwise regression analysis using a parametric proportional hazards model identified surgical stage as the most significant prognostic factor (P = 0.02). Univariate analysis showed that patients with surgical Stage IC had significantly worse prognosis (75.0%, 5 years) than those in surgical Stage IA (93.8% 5 YS) or IB (95.4% 5 years). In summary, this study demonstrates that surgical staging as recommended by FIGO is indicated to accurately determine the initial extent of disease in endometrial carcinoma. In addition, surgical staging is the strongest predictor of survival. Deep myometrial invasion appears to be a significant independent prognostic factor within surgical Stage I. The role of adjunctive radiotherapy in Stage I disease awaits the results from an ongoing multi-institutional, prospectively randomized trial.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Wolfson AH,Sightler SE,Markoe AM,Schwade JG,Averette HE,Ganjei P,Hilsenbeck SG

doi

10.1016/0090-8258(92)90276-o

subject

Has Abstract

pub_date

1992-05-01 00:00:00

pages

142-6

issue

2

eissn

0090-8258

issn

1095-6859

journal_volume

45

pub_type

杂志文章
  • PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

    abstract:OBJECTIVE:Aberrant expression of HER2/neu and PIK3CA gene products secondary to amplification/mutations are common in high-grade-serous-endometrial (USC) and ovarian-cancers (HGSOC). Because scant information is currently available in the literature on the potential negative effect of PIK3CA mutations on the activity o...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.01.002

    authors: Bonazzoli E,Cocco E,Lopez S,Bellone S,Zammataro L,Bianchi A,Manzano A,Yadav G,Manara P,Perrone E,Haines K,Espinal M,Dugan K,Menderes G,Altwerger G,Han C,Zeybek B,Litkouhi B,Ratner E,Silasi DA,Huang GS,Azodi M,

    更新日期:2019-04-01 00:00:00

  • IN MEMORIAM

    abstract::Copyright ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1997.4926

    authors: Wharton JT,Gershenson DM

    更新日期:1998-02-01 00:00:00

  • The NCI-MATCH trial and precision medicine in gynecologic cancers.

    abstract::The Precision Medicine Initiative is a National Cancer Institute (NCI) driven interdisciplinary collaborative effort to test the feasibility of trials incorporating genomic profiling when choosing patient therapies. The goal of the initiative is to generate the scientific evidence needed to move the concept of precisi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2018.01.008

    authors: Barroilhet L,Matulonis U

    更新日期:2018-03-01 00:00:00

  • Characteristics relating to ovarian cancer risk: implications for prevention and detection.

    abstract::Approximately 20,000 women are diagnosed with ovarian cancer in the United States each year, and some 12,000 women die because of it. Epithelial ovarian cancer, the most common histopathologic type, is uncommon before age 40 years, after which incidence rates increase steeply until age 70-79 years and then decrease so...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.1994.1334

    authors: Whittemore AS

    更新日期:1994-12-01 00:00:00

  • Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature.

    abstract::Paraneoplastic cerebellar degeneration (PCD) is a rare nonmetastatic neurological complication in cancer patients. Anti-Yo is one of the anti-onconeural antibodies found in PCD patients. It is believed that anti-Yo occurs almost always in women and is most likely associated with gynecologic or breast cancers, although...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.1999.5553

    authors: Cao Y,Abbas J,Wu X,Dooley J,van Amburg AL

    更新日期:1999-10-01 00:00:00

  • Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.

    abstract:OBJECTIVE:The objective of this study was to evaluate the impact of introducing HR-HPV testing in cytology regarding cervical cancer screening practice. METHODS:A pooled analysis of liquid-based cytology (LBC) and HR-HPV testing using data from 13 population-based cervical cancer screening studies conducted in China w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ygyno.2014.03.008

    authors: Pan QJ,Hu SY,Guo HQ,Zhang WH,Zhang X,Chen W,Cao J,Jiang Y,Zhao FH,Qiao YL

    更新日期:2014-05-01 00:00:00

  • Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies.

    abstract:OBJECTIVES:To determine the incidence and prognostic implications of positive mesorectal lymph nodes in patients undergoing total pelvic exenteration for recurrent gynecologic malignancies. METHODS:We performed a retrospective chart review of all patients who had undergone total pelvic exenteration for a gynecologic m...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.08.039

    authors: Mourton SM,Chi DS,Sonoda Y,Alektiar KM,Venkatraman ES,Barakat RR,Abu-Rustum NR

    更新日期:2006-03-01 00:00:00

  • Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.

    abstract:OBJECTIVE:Mucinous borderline ovarian tumor (mucinous-BOT) and invasive well-differentiated mucinous ovarian cancer (mucinous-OC) are often histopathologically misclassified. The objective of this study was to examine differences in clinico-pathological characteristics and outcomes of these two entities. METHODS:This ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.02.003

    authors: Matsuo K,Machida H,Mandelbaum RS,Grubbs BH,Roman LD,Sood AK,Gershenson DM

    更新日期:2019-05-01 00:00:00

  • Luteinized thecoma associated with sclerosing peritonitis--conservative surgical approach followed by corticosteroid and GnRH agonist treatment--a case report.

    abstract:BACKGROUND:Luteinized thecoma of the ovary associated with sclerosing peritonitis is a rare tumor that has no standard definitive treatment regimen. CASE:A 25 year-old patient diagnosed with luteinized thecoma and sclerosing peritonitis in the omentum. The patient received high dose corticosteroids (IV Hydrocortisone ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.04.014

    authors: Schonman R,Klein Z,Edelstein E,Czernobilsky B,Fishman A

    更新日期:2008-12-01 00:00:00

  • Cloacogenic adenocarcinoma of the vulva.

    abstract::Primary adenocarcinoma of the vulva is rare, and cloagocenic adenocarcinoma of the vulva is extremely rare. Here we report a vulvar tumor characterized by columnar cells with prominent brush border and the presence of goblet cells and endocrine cells, presenting the tubulovillous pattern and mucin histochemistry of en...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1999.5433

    authors: Willén R,Békássy,Carlén B,Bozoky B,Cajander S

    更新日期:1999-08-01 00:00:00

  • Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.

    abstract::Forty-three patients with ovarian cancer were entered on this trial and treated with intravenous (iv) cyclophosphamide (C) and doxorubicin (A), and intraperitoneal (ip) cisplatin (DDP), every 21 days for eight cycles. Following iv hydration, the cisplatin was administered through an intraperitoneal catheter in 2 L of ...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.1999.5613

    authors: Morgan RJ Jr,Braly P,Cecchi G,Leong L,Shibata S,Margolin K,Somlo G,McNamara M,Longmate J,Schinke S,Raschko J,Nagasawa S,Kogut N,Parker P,Stein A,Cho J,Smith E,Coluzzi P,Najera L,Johnson D,Womack E,Doroshow JH

    更新日期:1999-12-01 00:00:00

  • Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia.

    abstract:OBJECTIVE:While the importance of the sequence of administration of cisplatin and paclitaxel on the degree of observed neutropenia has been documented, there is limited information available in the oncology literature to determine whether there exists sequence-dependent toxicity for the combination of carboplatin plus ...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0090-8258(03)00517-1

    authors: Markman M,Elson P,Kulp B,Peterson G,Zanotti K,Webster K,Belinson J

    更新日期:2003-10-01 00:00:00

  • Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

    abstract:OBJECTIVE:Doxorubicin has reported activity in advanced and recurrent cervical cancer but hematologic toxicity has limited its use in some combinations. To determine the level of activity and potential for use in future combinations, a phase II trial of pegylated liposomal doxorubicin as second-line therapy in advanced...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2005.11.048

    authors: Rose PG,Blessing JA,Lele S,Abulafia O

    更新日期:2006-08-01 00:00:00

  • Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.

    abstract:OBJECTIVES:In this study we evaluated changes in serum Müllerian inhibiting substance (MIS) concentration in a large number of patients with granulosa cell tumors (GCT) to determine whether MIS is elevated at the time of presentation and whether MIS is an index of successful surgical resection and management of recurre...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5290

    authors: Lane AH,Lee MM,Fuller AF Jr,Kehas DJ,Donahoe PK,MacLaughlin DT

    更新日期:1999-04-01 00:00:00

  • An improved radioimmunoassay for human ovarian tumor antigen NB/70K.

    abstract::An improved assay for the measurement of human ovarian tumor antigen NB/70K (triton NB/70K assay) has been developed. This assay makes the accurate and reproducible estimation of serum NB/70K possible. Freezing and thawing of serum up to three times or refrigeration of diluted serum up to 7 days does not significantly...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(84)90160-4

    authors: Knauf S,Taillon-Miller P

    更新日期:1984-09-01 00:00:00

  • Types of pelvic exenterations: a reappraisal.

    abstract::Subgrouping of pelvic exenterations as supralevator (type I), infralevator (type II), with vulvectomy (type III), and, an added category, extended can be helpful to facilitate communication when referring to these patients. It also can facilitate a more detailed analysis of operative risk factors, complications, and r...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90368-u

    authors: Magrina JF

    更新日期:1990-06-01 00:00:00

  • Stage II endometrial carcinoma: prognostic factors and the results of treatment.

    abstract::Results of treatment and potential prognostic factors in 54 patients with clinical stage II endometrial carcinoma were analyzed. During the period analyzed, three different treatment techniques were used. The highest cure rate (70.6%) was observed in patients treated with simple hysterectomy and bilateral salpingo-oop...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90045-m

    authors: Andersen ES

    更新日期:1990-08-01 00:00:00

  • Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.

    abstract:OBJECTIVE:This study was performed to define the subgroups of patients who benefit from postoperative adjuvant chemotherapy in stage I and II endometrial carcinoma. METHODS:A retrospective review of 170 International Federation of Gynecology and Obstetrics (FIGO) stage I and II endometrial carcinoma patients treated b...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.05.040

    authors: Aoki Y,Watanabe M,Amikura T,Obata H,Sekine M,Yahata T,Fujita K,Tanaka K

    更新日期:2004-08-01 00:00:00

  • Insomnia and its association with quality of life in women with ovarian cancer.

    abstract:OBJECTIVES:Insomnia is common in women with ovarian cancer but there are limited prospective data on the frequency and degree of impact on patients. Our objective was to determine the prevalence of insomnia over the first three years after a diagnosis of ovarian cancer; and the relationship between insomnia and quality...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.06.500

    authors: Ross TL,DeFazio A,Friedlander M,Grant P,Nagle CM,Williams M,Webb PM,Beesley VL,OPAL Study Group.

    更新日期:2020-09-01 00:00:00

  • Specialist surgery for ovarian cancer in England.

    abstract:OBJECTIVE:The aim of this study is to evaluate the impact of the 1999 national recommendations for ovarian cancer surgery in England to be performed by specialist surgeons in specialist centres. METHODS:A retrospective analysis of English cancer registry records, Hospital Episode Statistics (HES) data for all English ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2015.03.003

    authors: Butler J,Gildea C,Poole J,Meechan D,Nordin A

    更新日期:2015-09-01 00:00:00

  • Primary lymphoma of the uterine cervix.

    abstract::Primary lymphoma of the cervix is very rare. A case report is presented and 24 cases published in the English literature are reviewed. Evaluation, staging, treatment, and prognosis of this rare tumor are discussed. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(87)90080-1

    authors: Mann R,Roberts WS,Gunasakeran S,Tralins A

    更新日期:1987-01-01 00:00:00

  • Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.

    abstract:PURPOSE:A phase II trial was conducted to evaluate the anti-tumor activity and adverse effects of capecitabine in women with measurable platinum-sensitive ovarian cancer or platinum-sensitive primary peritoneal cancer and to explore the ability of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and th...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.ygyno.2004.11.037

    authors: Garcia AA,Blessing JA,Lenz HJ,Darcy KM,Mannel RS,Miller DS,Husseinzadeh N,Gynecologic Oncology Group.

    更新日期:2005-03-01 00:00:00

  • Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study.

    abstract:OBJECTIVE:The aim of this retrospective multicenter study was to assess whether the pre-chemotherapy hemoglobin levels have any impact on the clinical outcome of patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen. METHODS:The study was conducted on 315 patients who...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2005.04.012

    authors: Gadducci A,Sartori E,Landoni F,Zola P,Maggino T,Colombo N,Fanucchi A,Chiudinelli F,Lapresa M,Maria Ferrero A

    更新日期:2005-07-01 00:00:00

  • Fas-mediated pathway and apoptosis in normal, hyperplastic, and neoplastic endometrium.

    abstract:OBJECTIVES:Abnormalities in the control of cell proliferation and apoptosis have been suggested to contribute to the development and progression of neoplasia. There are at least two pathways that activate apoptosis. The first is a mitochondria-dependent route governed by bcl-2 family proteins. The second is a parallel ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(03)00411-6

    authors: Atasoy P,Bozdoğan O,Erekul S,Bozdoğan N,Bayram M

    更新日期:2003-11-01 00:00:00

  • Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.

    abstract:OBJECTIVE:We sought to determine whether DNA ploidy correlates with the four molecular subgroups of endometrial carcinoma (EC) as determined using ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). METHODS:90 cases of EC previously characterized by clinicopathological parameters, outcomes, and ProMi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.06.020

    authors: Proctor L,Pradhan M,Leung S,Cheng A,Lee CH,Soslow RA,Gilks CB,Talhouk A,McAlpine JM,Danielsen HE,Hoang LN

    更新日期:2017-09-01 00:00:00

  • Prevalence of antibodies to herpes simplex virus and frequency of HLA antigens in patients with preinvasive and invasive cervical cancer.

    abstract::Previous herpes simplex virus type 2 (HSV-2) infections are known to predispose women for the development of cervical cancer, but causal relationship between the virus and the cancer has never been proven. Forty-six patients with cervical carcinoma (13 with preinvasive lesions and 33 with various stages of invasive di...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(84)90047-7

    authors: Vass-Sørensen M,Abeler V,Berle E,Pedersen B,Davy M,Thorsby E,Norrild B

    更新日期:1984-07-01 00:00:00

  • Clinical value of intraoperative gross examination in endometrial cancer.

    abstract::We present the largest multicenter study evaluating whether intraoperative visual estimation can accurately assess the depth of myometrial invasion in patients with endometrial cancer. The study population consisted of 403 consecutive women who underwent total hysterectomy for endometrial cancer. After the uterus was ...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1006/gyno.1999.5694

    authors: Franchi M,Ghezzi F,Melpignano M,Cherchi PL,Scarabelli C,Apolloni C,Zanaboni F

    更新日期:2000-03-01 00:00:00

  • Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme.

    abstract:OBJECTIVE:This two-arm longitudinal study was performed within a regional organized cervical-cancer-prevention program in which HPV-DNA test is used in primary screening. The aim was to analyze the diagnostic performances of p16INK4a/Ki-67 dual-test and E6/E7-mRNA test in identifying CIN2+ lesion among HPV-DNA positive...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.11.030

    authors: Zappacosta R,Caraceni D,Ciccocioppo L,Rotondo T,Capanna S,Gatta DM,D'Angelo C,Rosini S

    更新日期:2013-03-01 00:00:00

  • Standing on the shoulders of giants: Mentorship advice from leaders in the field.

    abstract::This commentary is presenting opinions and advice on mentorship in the field of gynecologic oncology. Eleven academic gynecologic oncologists from across the country were interviewed and their thoughts about mentorship were recorded with recurring themes and ideas described in this commentary. Trust, respect, and mutu...

    journal_title:Gynecologic oncology

    pub_type: 社论

    doi:10.1016/j.ygyno.2021.01.017

    authors: Boitano TKL,Chi DS,Copeland LJ,Straughn JM Jr

    更新日期:2021-01-27 00:00:00

  • Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: the first report of a case.

    abstract::Hypersensitivity reactions to intravenous administration of carboplatin (CP) have been previously reported. However, hypersensitivity reaction to intraperitoneal administration of CP has not yet been reported. A 66-year-old woman diagnosed with ovarian carcinoma underwent six courses of intraperitoneal administration ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.1998.5273

    authors: Shukunami K,Kurokawa T,Kawakami Y,Kubo M,Kotsuji F

    更新日期:1999-03-01 00:00:00